Drugs / STI-6129
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05692908 | Sep 2023 → Sep 2024 | AL amyloidosis | Sorrento Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 1 | NCT05584709 | Mar 2023 → Aug 2025 | neoplasm | Sorrento Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT05519527 | Aug 2022 → Feb 2023 | T-cell acute lymphoblastic leukemia, acute myeloid leukemia | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05565807 | Feb 2023 → Dec 2026 expected | refractory plasma cell neoplasm | Zhejiang ACEA Pharmaceutical Co. Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05308225 | Feb 2023 → Dec 2025 overdue | plasma cell myeloma | Sorrento Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04316442 | Apr 2021 → Sep 2024 | AL amyloidosis | Sorrento Therapeutics, Inc. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STI-6129 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05584709 ↗ |
| Modality | Other / unclassified | “anti-CD38-Duostatin 5.2 antibody-drug conjugate (ADC)” NCT04316442 ↗ |
| Route | Intravenous | “Intravenous infusion to be given with prophylaxis for infusion reactions if necessary.” NCT04316442 ↗ |
| Target | CD38 | “anti-CD38-Duostatin 5.2 antibody-drug conjugate (ADC)” NCT04316442 ↗ |